Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known ... used a "difference-in-differences" framework to compare GLP-1 adopters and non-adopters and found that ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Popular GLP-1 ... compare to treatments that are already available. There's at least one study underway to try to answer some of those questions.Other studies are also testing to see whether drugs ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control. The stock has ...